The radionuclide technetium-99m continues to be the mainstay of routine clinical nuclear medicine. This research program was originally conceived on the premise that the usefulness of this radionuclide in diagnosis can only be maintained by conducting a rigorous study of the basic chemistry of the element and incorporating this knowledge into the design of new radiopharmaceuticals. This is equally true of therapeutic applications based on the use of radionuclides of its congener rhenium. In this next period the applicants proposed to concentrate primarily on two broad areas of chemistry: low valent chemistry in oxidation states (+1) and (+2), including the study of complexes continuing weak-field ligands that may provide routes into the production of new classes of complexes in aqueous media from routine precursors such as pertechnetate ion: and organohydrazine chemistry, a highly complex area that has begun to be used in certain radiopharmaceutical applications, for example, the chelate 6-hydrazinonicotinamide (HYNIC). In applications of the chemistry, the work will include an investigation of monoamide-monoamine bisthiol (MAMA or AAST) conjugated ligands targeted to 5HT-1A receptors in the brain. Factors affecting localization such as structure, choice of chelate lipophilicity, the pKa of the complex under physiological conditions, and selectivity against other receptor types will be studied. In parallel, a solid state synthesis for producing high-specific-activity samples of technetium complexes designed for receptor targeting will be explored. This is vital in circumstances where unlabeled precursor ligand could compete with the final complex for sites of occupation. The last section among the applications will focus on tumor detection. First, the 5HT-1A ligands developed for studying the brain will be evaluated for their ability to detect neuroendocrine mediated cancer of the prostate. Second, a program is being established to study small-molecule detection of cancer, in the first instance using conjugated analogs of iodinated compounds that have already bee shown by others to be avidly taken up by melanoma cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034970-24
Application #
6512439
Study Section
Special Emphasis Panel (ZRG1-DMG (06))
Program Officer
Menkens, Anne E
Project Start
1977-02-01
Project End
2005-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
24
Fiscal Year
2002
Total Cost
$493,378
Indirect Cost
Name
Harvard University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Zaheer, A; Lenkinski, R E; Mahmood, A et al. (2001) In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol 19:1148-54
Packard, A B; Barbarics, E; Kronauge, J F et al. (1997) Comparison of uptake of 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model. Nucl Med Biol 24:21-5
Herman, L W; Sharma, V; Kronauge, J F et al. (1995) Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J Med Chem 38:2955-63
Verdera, S; Lopez, J J; Tagle, R et al. (1994) Radiopharmacological evaluation in dogs of a new renal function agent. J Nucl Biol Med 38:79-85
Piwnica-Worms, D P; Kronauge, J F; LeFurgey, A et al. (1994) Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging 12:641-52
Barbarics, E; Kronauge, J F; Costello, C E et al. (1994) In vivo metabolism of the technetium isonitrile complex [Tc(2-ethoxy-2-methyl-1-isocyanopropane)6]+. Nucl Med Biol 21:583-91
Packard, A B; Kronauge, J F; Limpa-Amara, N et al. (1993) Tumor uptake of 99mTc-MIBI and 201Tl by a 9L gliosarcoma brain tumor model in rats. Nucl Med Biol 20:773-6
Verdera, S; Leon, A; Kronauge, J F et al. (1993) Radiopharmacological studies of 99mTc-CPI: experience with isolated rat atrial tissue. Nucl Med Biol 20:127-32
Carvalho, P A; Chiu, M L; Kronauge, J F et al. (1992) Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 33:1516-22
Delmon-Moingeon, L I; Mahmood, A; Davison, A et al. (1991) Strategies for labeling monoclonal antibodies and antibody-like molecules with technetium-99m. J Nucl Biol Med 35:47-59

Showing the most recent 10 out of 16 publications